Therapeutic targeting of cancer stem cells

Frontiers in Oncology

Volumn 1, Issue JUN, 2011, Pages

  Maugeri Saccà, Marcello ^a   Zeuner, Ann ^a   De Maria, Ruggero ^a,b  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b Mediterranean Institute of Oncology   (Italy)

Author keywords

Cancer stem cells; Chemoresistance; Molecular targeted agents; Self renewal pathways

Indexed keywords

EID: 84888203468     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2011.00010     Document Type: Note

References (95)

1. Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J., and Clarke, M. F. (2003). Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. U.S.A. 100, 3983-3988.
2. Anderson, K., Lutz, C., van Delft, F. W., Bateman, C. M., Guo, Y., Colman, S. M., Kempski, H., Moorman, A. V., Titley, I., Swansbury, J., Kearney, L., Enver, T., and Greaves, M. (2011). Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature 469, 356-361.
3. Arrieta, O., González-De la Rosa, C. H., Aréchaga-Ocampo, E., Villanueva-Rodríguez, G., Cerón-Lizárraga, T. L., Martínez-Barrera, L., Vázquez-Manríquez, M. E., Ríos-Trejo, M. A., Alvarez-Avitia, M. A., Hernández-Pedro, N., Rojas-Marín, C., and De la Garza, J. (2010). Randomized phase II trial of All-trans-retinoic acid with chemotherapy based on paclitaxel and cisplatin as first-line treatment in patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 28, 3463-3471.
4. Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., Lu, K., Schmutzler, R. K., Matulonis, U., Wickens, M., and Tutt, A. (2010). Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 376, 245-251.
5. Baiocchi, M., Biffoni, M., Ricci-Vitiani, L., Pilozzi, E., and De Maria, R. (2010). New models for cancer research: human cancer stem cell xenografts. Curr. Opin. Pharmacol. 10, 380-384.
6. Bao, S., Wu, Q., McLendon, R. E., Hao, Y., Shi, Q., Hjelmeland, A. B., Dewhirst, M. W., Bigner, D. D., and Rich, J. N. (2006). Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444, 756-760.
7. Bar, E. E., Chaudhry, A., Lin, A., Fan, X., Schreck, K., Matsui, W., Piccirillo, S., Vescovi, A. L., DiMeco, F., Olivi, A., and Eberhart, C. G. (2007). Cyclopamine-mediated Hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma. Stem Cells 25, 2524-2533.
8. Berlin, J., Bendell, J., Hart, L. L., Firdaus, I., Gore, I., Hermann, R. C., Mackey, H., Yauch, B., Graham, R. A., and Bray, G. L. (2010). A phase 2, randomized, double-blind, placebo-controlled study of hedgehog pathway inhibitor (HPI) GDC-0449 in patients with previously untreated metastatic colorectal cancer (MCRC). Ann. Oncol. 21(Suppl. 8), Abstract LBA21.
9. Bonnet, D., and Dick, J. E. (1997). Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 3, 730-737.
10. Broadley, K. W., Hunn, M. K., Farrand, K. J., Price, K. M., Grasso, C., Miller, R. J., Hermans, I. F., and McConnell, M. J. (2011). Side population is not necessary or sufficient for a cancer stem cell phenotype in glioblastoma multiforme. Stem Cells 29, 452-461.
11. Calcagno, A. M., Salcido, C. D., Gillet, J. P., Wu, C. P., Fostel, J. M., Mumau, M. D., Gottesman, M. M., Varticovski, L., and Ambudkar, S. V. (2010). Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics. J. Natl. Cancer Inst. 102, 1637-1652.
12. Chen, J. K., Taipale, J., Cooper, M. K., and Beachy, P. A. (2002). Inhibition of hedgehog signaling by direct binding of cyclopamine to smoothened. Genes Dev. 16, 2743-2748.
13. Cicalese, A., Bonizzi, G., Pasi, C. E., Faretta, M., Ronzoni, S., Giulini, B., Brisken, C., Minucci, S., Di Fiore, P. P., and Pelicci, P. G. (2009). The tumor suppressor p53 regulates polarity of self-renewing divisions in mammary stem cells. Cell 138, 1083-1095.
14. Daya-Grosjean, L., and Couvé-Privat, S. (2005). Sonic hedgehog signaling in basal cell carcinomas. Cancer Lett. 225, 181-192.
15. Dekaney, C. M., Gulati, A. S., Garrison, A. P., Helmrath, M. A., and Henning, S. J. (2009). Regeneration of intestinal stem/progenitor cells following doxorubicin treatment of mice. Am. J. Physiol. Gastrointest. Liver Physiol. 297, 461-470.
16. Dembinski, J. L., and Krauss, S. (2009). Characterization and functional analysis of a slow cycling stem cell-like subpopulation in pancreas adenocarcinoma. Clin. Exp. Metastasis 26, 611-623.
17. Dennler, S., André, J., Alexaki, I., Li, A., Magnaldo, T., ten Dijke, P., Wang, X. J., Verrecchia, F., and Mauviel, A. (2007). Induction of sonic Hedgehog mediators by transforming growth factor-β: Smad3-dependent activation of Gli2 and Gli1 expression in vitro and in vivo. Cancer Res. 67, 6981-6696.
18. de Sousa, E. M., Vermeulen, L., Richel, D., and Medema, J. P. (2011). Targeting Wnt signaling in colon cancer stem cells. Clin. Cancer Res. 17, 647-653.
19. Dierks, C., Grbic, J., Zirlik, K., Beigi, R., Englund, N. P., Guo, G. R., Veelken, H., Engelhardt, M., Mertelsmann, R., Kelleher, J. F., Schultz, P., and Warmuth, M. (2007). Essential role of stromally induced hedgehog signaling in B-cell malignancies. Nat. Med. 13, 944-951.
20. El Hallani, S., Boisselier, B., Peglion, F., Rousseau, A., Colin, C., Idbaih, A., Marie, Y., Mokhtari, K., Thomas, J. L., Eichmann, A., Delattre, J. Y., Maniotis, A. J., and Sanson, M. (2010). A new alternative mechanism in glioblastoma vascularization: tubular vasculogenic mimicry. Brain 133, 973-982.
21. Eramo, A., Haas, T. L., and De Maria, R. (2010). Lung cancer stem cells: tools and targets to fight lung cancer. Oncogene 29, 4625-4635.
22. Eramo, A., Lotti, F., Sette, G., Pilozzi, E., Biffoni, M., Di Virgilio, A., Conticello, C., Ruco, L., Peschle, C., and De Maria, R. (2008). Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ. 15, 504-514.
23. Eramo, A., Ricci-Vitiani, L., Zeuner, A., Pallini, R., Lotti, F., Sette, G., Pilozzi, E., Larocca, L. M., Peschle, C., and De Maria, R. (2006). Chemotherapy resistance of glioblastoma stem cells. Cell Death Differ. 13, 1238-1241.
24. Essers, M. A., and Trumpp, A. (2010). Targeting leukemic stem cells by breaking their dormancy. Mol. Oncol. 4, 443-450.
25. Eyler, C. E., and Rich, J. N. (2008). Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. J. Clin. Oncol. 26, 2839-2845.
26. Fan, X., Khaki, L., Zhu, T. S., Soules, M. E., Talsma, C. E., Gul, N., Koh, C., Zhang, J., Li, Y. M., Maciaczyk, J., Nikkhah, G., Dimeco, F., Piccirillo, S., Vescovi, A. L., and Eberhart, C. G. (2010). Notch pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts. Stem Cells 28, 5-16.
27. Farnie, G., Clarke, R. B., Spence, K., Pinnock, N., Brennan, K., Anderson, N. G., and Bundred, N. J. (2007). Novel cell culture technique for primary ductal carcinoma in situ: role of Notch and epidermal growth factor receptor signaling pathways. J. Natl. Cancer Inst. 99, 616-627.
28. Feldmann, G., Dhara, S., Fendrich, V., Bedja, D., Beaty, R., Mullendore, M., Karikari, C., Alvarez, H., Iacobuzio-Donahue, C., Jimeno, A., Gabrielson, K. L., Matsui, W., and Maitra, A. (2007). Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers. Cancer Res. 67, 2187-2196.
29. Fischer, M., Yen, W. C., Kapoun, A. M., Wang, M., O'Young, G., Lewicki, J., Gurney, A., and Hoey, T. (2011). Anti-DLL4 inhibits growth and reduces tumor-initiating cell frequency in colorectal tumors with oncogenic KRAS mutations. Cancer Res. 71, 1520-1525.
30. Frank-Kamenetsky, M., Zhang, X. M., Bottega, S., Guicherit, O., Wichterle, H., Dudek, H., Bumcrot, D., Wang, F. Y., Jones, S., Shulok, J., Rubin, L. L., and Porter, J. A. (2002). Small-molecule modulators of hedgehog signaling: identification and characterization of smoothened agonists and antagonists. J. Biol. 1, 10.
31. Galli, R., Binda, E., Orfanelli, U., Cipelletti, B., Gritti, A., De Vitis, S., Fiocco, R., Foroni, C., Dimeco, F., and Vescovi, A. (2004). Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res. 64, 7011-7021.
32. Gallmeier, E., Hermann, P. C., Mueller, M. T., Machado, J. G., Ziesch, A., De Toni, E. N., Palagyi, A., Eisen, C., Ellwart, J. W., Rivera, J., Rubio-Viqueira, B., Hidalgo, M., Bunz, F., Göke, B., and Heeschen, C. (2011). Inhibition of ataxia telangiectasia-and Rad3-related function abrogates the in vitro and in vivo tumorigenicity of human colon cancer cells through depletion of the CD133(+) tumor-initiating cell fraction. Stem Cells 29, 418-429.
33. Gao, M. Q., Choi, Y. P., Kang, S., Youn, J. H., and Cho, N. H. (2010). CD24+ cells from hierarchically organized ovarian cancer are enriched in cancer stem cells. Oncogene 29, 2672-2680.
34. Graham, R. A., Lum, B. L., Cheeti, S., Jin, J. Y., Jorga, K., Von Hoff, D. D., Rudin, C. M., Reddy, J. C., Low, J. A., and Lorusso, P. M. (2011). Pharmacokinetics of Hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors: the role of alpha-1-acid glycoprotein binding. Clin. Cancer Res. 17, 2512-2520.
35. Graziani, I., Eliasz, S., De Marco, M. A., Chen, Y., Pass, H. I., De May, R. M., Strack, P. R., Miele, L., and Bocchetta, M. (2008). Opposite effects of Notch-1 and Notch-2 on mesothelioma cell survival under hypoxia are exerted through the Akt pathway. Cancer Res. 68, 9678-9685.
36. Hahn, H., Wicking, C., Zaphiropoulous, P. G., Gailani, M. R., Shanley, S., Chidambaram, A., Vorechovsky, I., Holmberg, E., Unden, A. B., Gillies, S., Negus, K., Smyth, I., Pressman, C., Leffell, D. J., Gerrard, B., Goldstein, A. M., Dean, M., Toftgard, R., Chenevix-Trench, G., Wainwright, B., and Bale, A. E. (1996). Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell 85, 841-851.
37. Hirschmann-Jax, C., Foster, A. E., Wulf, G. G., Nuchtern, J. G., Jax, T. W., Gobel, U., Goodell, M. A., and Brenner, M. K. (2004). A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc. Natl. Acad. Sci. U.S.A. 101, 14228-14233.
38. Hoeijmakers, J. H. (2001). Genome maintenance mechanisms for preventing cancer. Nature 411, 366-374.
39. Hoey, T., Yen, W. C., Axelrod, F., Basi, J., Donigian, L., Dylla, S., Fitch-Bruhns, M., Lazetic, S., Park, I. K., Sato, A., Satyal, S., Wang, X., Clarke, M. F., Lewicki, J., and Gurney, A. (2009). DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency. Cell Stem Cell 5, 168-177.
40. Ingham, P. W., and McMahon, A. P. (2001). Hedgehog signaling in animal development: paradigms and principles. Genes Dev. 15, 3059-3087.
41. Jamieson, C. H., Weissman, I. L., and Passegue, E. (2004). Chronic versus acute myelogenous leukemia: a question of self-renewal. Cancer Cell 6, 531-533.
42. Ji, Z., Mei, F. C., Xie, J., and Cheng, X. (2007). Oncogenic KRAS activates Hedgehog signaling pathway in pancreatic cancer cells. J. Biol. Chem. 282, 14048-14055.
43. Kaye, S. B., Fehrenbacher, L., Holloway, R., Horowitz, N., Karlan, B., Amit, A., Slomovitz, B., Chang, I., Yauch, R. L., and Reddy, J. C. (2010). A phase 2, randomized, placebo-controlled study of Hedgehog (HH) pathway inhibitor GDC-0449 as maintenance therapy in patients with ovarian cancer in 2nd or 3rd complete remission (CR). Ann. Oncol. 21(Suppl. 8), Abstract LBA25.
44. Koch, U., and Radtke, F. (2007). Notch and cancer: a double-edged sword. Cell. Mol. Life Sci. 64, 2746-2762.
45. Korkaya, H., and Wicha, M. S. (2009). HER-2, notch, and breast cancer stem cells: targeting an axis of evil. Clin. Cancer Res. 15, 1845-1847.
46. Lane, A. A., and Chabner, B. A. (2009). Histone deacetylase inhibitors in cancer therapy. J. Clin. Oncol. 27, 5459-5468.
47. Lauth, M., Bergström, A., Shimokawa, T., and Toftgård, R. (2007). Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists. Proc. Natl. Acad. Sci. U.S.A. 104, 8455-8460.
48. Li, J. L., Jubb, A. M., and Harris, A. L. (2010). Targeting DLL4 in tumors shows preclinical activity but potentially significant toxicity. Future Oncol. 6, 1099-1103.
49. Li, Z., Bao, S., Wu, Q., Wang, H., Eyler, C., Sathornsumetee, S., Shi, Q., Cao, Y., Lathia, J., McLendon, R. E., Hjelmeland, A. B., and Rich, J. N. (2009). Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell 15, 501-513.
50. Liu, S., Dontu, G., Mantle, I. D., Patel, S., Ahn, N. S., Jackson, K. W., Suri, P., and Wicha, M. S. (2006). Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res. 66, 6063-6071.
51. Lombardo, Y., Scopelliti, A., Cammareri, P., Todaro, M., Iovino, F., Ricci-Vitiani, L., Gulotta, G., Dieli, F., De Maria, R., and Stassi, G. (2011). Bone morphogenetic protein 4 induces differentiation of colorectal cancer stem cells and increases their response to chemotherapy in mice. Gastroenterology 140, 297-309.
52. Magnifico, A., Albano, L., Campaner, S., Delia, D., Castiglioni, F., Gasparini, P., Sozzi, G., Fontanella, E., Menard, S., and Tagliabue, E. (2009). Tumour-initiating cells of HER2-positive carcinoma cell lines express the highest oncoprotein levels and are trastuzumab sensitive. Clin. Cancer Res. 15, 2010-2021.
53. Merchant, A. A., and Matsui, W. (2010). Targeting Hedgehog-a cancer stem cell pathway. Clin. Cancer Res. 16, 3130-3140.
54. Moitra, K., Lou, H., and Dean, M. (2011). Multidrug efflux pumps and cancer stem cells: insights into multidrug resistance and therapeutic development. Clin. Pharmacol. Ther. 89, 491-502.
55. Moon, R. T., Bowerman, B., Boutros, M., and Perrimon, N. (2002). The promise and perils of Wnt signaling through β-catenin. Science 296, 1644-1646.
56. O'Shaughnessy, J., Osborne, C., Pippen, J. E., Yoffe, M., Patt, D., Rocha, C., Koo, I. C., Sherman, B. M., and Bradley, C. (2011). Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N. Engl. J. Med. 364, 205-214.
57. Pannuti, A., Foreman, K., Rizzo, P., Osipo, C., Golde, T., Osborne, B., and Miele, L. (2010). Targeting Notch to target cancer stem cells. Clin. Cancer Res. 16, 3141-3152.
58. Parr, C., Watkins, G., and Jiang, W. G. (2004). The possible correlation of Notch-1 and Notch-2 with clinical outcome and tumour clinicopathological parameters in human breast cancer. Int. J. Mol. Med. 14, 779-786.
59. Peacock, C. D., Wang, Q., Gesell, G. S., Corcoran-Schwartz, I. M., Jones, E., Kim, J., Devereux, W. L., Rhodes, J. T., Huff, C. A., Beachy, P. A., Watkins, D. N., and Matsui, W. (2007). Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma. Proc. Natl. Acad. Sci. U.S.A. 104, 4048-4053.
60. Perou, C. M. (2011). Molecular stratification of triple-negative breast cancers. Oncologist 16(Suppl.), 61-70.
61. Piccirillo, S. G., Reynolds, B. A., Zanetti, N., Lamorte, G., Binda, E., Broggi, G., Brem, H., Olivi, A., Dimeco, F., and Vescovi, A. L. (2006). Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature 444, 761-765.
62. Quintana, E., Shackleton, M., Foster, H. R., Fullen, D. R., Sabel, M. S., Johnson, T. M., and Morrison, S. J. (2010). Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. Cancer Cell 18, 510-523.
63. Ricci-Vitiani, L., Lombardi, D. G., Pilozzi, E., Biffoni, M., Todaro, M., Peschle, C., and De Maria, R. (2007). Identification and expansion of human colon-cancer-initiating cells. Nature 445, 111-115.
64. Ricci-Vitiani, L., Pallini, R., Biffoni, M., Todaro, M., Invernici, G., Cenci, T., Maira, G., Parati, E. A., Stassi, G., Larocca, L. M., and De Maria, R. (2010). Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 468, 824-828.
65. Riobo, N. A., Lu, K., Ai, X., Haines, G. M., and Emerson, C. P. Jr. (2006). Phosphoinositide 3-kinase and AKT are essential for sonic Hedgehog signaling. Proc. Natl. Acad. Sci. U.S.A. 103, 4505-4510.
66. Rizzo, P., Miao, H., D'Souza, G., Osipo, C., Song, L. L., Yun, J., Zhao, H., Mascarenhas, J., Wyatt, D., Antico, G., Hao, L., Yao, K., Rajan, P., Hicks, C., Siziopikou, K., Selvaggi, S., Bashir, A., Bhandari, D., Marchese, A., Lendahl, U., Qin, J. Z., Tonetti, D. A., Albain, K., Nickoloff, B. J., and Miele, L. (2008). Cross-talk between notch and the estrogen receptor in breast cancer suggests novel therapeutic approaches. Cancer Res. 68, 5226-5235.
67. Rudin, C. M., Hann, C. L., Laterra, J., Yauch, R. L., Callahan, C. A., Fu, L., Holcomb, T., Stinson, J., Gould, S. E., Coleman, B., LoRusso, P. M., Von Hoff, D. D., de Sauvage, F. J., and Low, J. A. (2009). Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N. Engl. J. Med. 36, 1173-1178.
68. Sansone, P., Storci, G., Tavolari, S., Guarnieri, T., Giovannini, C., Taffurelli, M., Ceccarelli, C., Santini, D., Paterini, P., Marcu, K. B., Chieco, P., and Bonafè, M. (2007). IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J. Clin. Invest. 117, 3988-4002.
69. Sanz, M. A., Martin, G., Gonzalez, M., León, A., Rayón, C., Rivas, C., Colomer, D., Amutio, E., Capote, F. J., Milone, G. A., De La Serna, J., Román, J., Barragán, E., Bergua, J., Escoda, L., Parody, R., Negri, S., Calasanz, M. J., and Bolufer, P. (2004). Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood 103, 1237-1243.
70. Signore, M., Ricci-Vitiani, L., and De Maria, R. (2011). Targeting apoptosis pathways in cancer stem cells. Cancer Lett. doi: 10.1016/j.canlet.2011.01.013 [Epub ahead of print].
71. Singh, S. K., Clarke, I. D., Terasaki, M., Bonn, V. E., Hawkins, C., Squire, J., and Dirks, P. B. (2003). Identification of a cancer stem cell in human brain tumors. Cancer Res. 63, 5821-5828.
72. Soda, Y., Marumoto, T., Friedmann-Morvinski, D., Soda, M., Liu, F., Michiue, H., Pastorino, S., Yang, M., Hoffman, R. M., Kesari, S., and Verma, I. M. (2011). Transdifferentiation of glioblastoma cells into vascular endothelial cells. Proc. Natl. Acad. Sci. U.S.A. 108, 4274-4280.
73. Stanton, B. Z., Peng, L. F., Maloof, N., Nakai, K., Wang, X., Duffner, J. L., Taveras, K. M., Hyman, J. M., Lee, S. W., Koehler, A. N., Chen, J. K., Fox, J. L., Mandinova, A., and Schreiber, S. L. (2009). A small molecule that binds Hedgehog and blocks its signaling in human cells. Nat. Chem. Biol. 5, 154-156.
74. Thompson, M. C., Fuller, C., Hogg, T. L., Dalton, J., Finkelstein, D., Lau, C. C., Chintagumpala, M., Adesina, A., Ashley, D. M., Kellie, S. J., Taylor, M. D., Curran, T., Gajjar, A., and Gilbertson, R. J. (2006). Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. J. Clin. Oncol. 24, 1924-1931.
75. Todaro, M., Iovino, F., Eterno, V., Cammareri, P., Gambara, G., Espina, V., Gulotta, G., Dieli, F., Giordano, S., De Maria, R., and Stassi, G. (2010). Tumorigenic and metastatic activity of human thyroid cancer stem cells. Cancer Res. 70, 8874-8885.
76. Todaro, M., Lombardo, Y., Francipane, M. G., Alea, M. P., Cammareri, P., Iovino, F., Di Stefano, A. B., Di Bernardo, C., Agrusa, A., Condorelli, G., Walczak, H., and Stassi, G. (2008). Apoptosis resistance in epithelial tumors is mediated by tumor-cell-derived interleukin-4. Cell Death Differ. 15, 762-772.
77. Todaro, M., Perez Alea, M., Di Stefano, A. B., Cammareri, P., Vermeulen, L., Iovino, F., Tripodo, C., Russo, A., Gulotta, G., Medema, J. P., and Stassi, G. (2007). Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell 1, 389-402.
78. Tutt, A., Robson, M., Garber, J. E., Domchek, S. M., Audeh, M. W., Weitzel, J. N., Friedlander, M., Arun, B., Loman, N., Schmutzler, R. K., Wardley, A., Mitchell, G., Earl, H., Wickens, M., and Carmichael, J. (2010). Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376, 235-244.
79. Vermeulen, L., De Sousa E Melo, F., van der Heijden, M., Cameron, K., de Jong, J. H., Borovski, T., Tuynman, JB., Todaro, M., Merz, C., Rodermond, H., Sprick, M. R., Kemper, K., Richel, D. J., Stassi, G., and Medema, J. P. (2010). Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat. Cell Biol. 12, 468-476.
80. Vilmar, A., and Sørensen, J. B. (2009). Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature. Lung Cancer 64, 131-139.
81. Von Hoff, D. D., LoRusso, P. M., Rudin, C. M., Reddy, J. C., Yauch, R. L., Tibes, R., Weiss, G. J., Borad, M. J., Hann, C. L., Brahmer, J. R., Mackey, H. M., Lum, B. L., Darbonne, W. C., Marsters, J. C. Jr., de Sauvage, F. J., and Low, J. A. (2009). Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N. Engl. J. Med. 361, 1164-1172.
82. Wang, J., Wakeman, T. P., Lathia, J. D., Hjelmeland, A. B., Wang, X. F., White, R. R., Rich, J. N., and Sullenger, B. A. (2010a). Notch promotes radioresistance of glioma stem cells. Stem Cells 28, 17-28.
83. Wang, R., Chadalavada, K., Wilshire, J., Kowalik, U., Hovinga, K. E., Geber, A., Fligelman, B., Leversha, M., Brennan, C., and Tabar, V. (2010b). Glioblastoma stem-like cells give rise to tumour endothelium. Nature 468, 829-833.
84. Wilson, A., Laurenti, E., Oser, G., van der Wath, R. C., Blanco-Bose, W., Jaworski, M., Offner, S., Dunant, C. F., Eshkind, L., Bockamp, E., Lió, P., Macdonald, H. R., and Trumpp, A. (2008). Hematopoietic stem cells reversibly switch from dormancy to self-renewal during homeostasis and repair. Cell 135, 1118-1129.
85. Wu, C. P., Calcagno, A. M., and Ambudkar, S. V. (2008). Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies. Curr. Mol. Pharmacol. 1, 93-105.
86. Wulf, G. G., Wang, R. Y., Kuehnle, I., Weidner, D., Marini, F., Brenner, M. K., Andreeff, M., and Goodell, M. A. (2001). A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia. Blood 98, 1166-1173.
87. Xie, J., Johnson, R. L., Zhang, X., Bare, J. W., Waldman, F. M., Cogen, P. H., Menon, A. G., Warren, R. S., Chen, L. C., Scott, M. P., and Epstein, E. H. Jr. (1997). Mutations of the PATCHED gene in several types of sporadic extracutaneous tumors. Cancer Res. 57, 2369-2372.
88. Xie, J., Murone, M., Luoh, S. M., Ryan, A., Gu, Q., Zhang, C., Bonifas, J. M., Lam, C. W., Hynes, M., Goddard, A., Rosenthal, A., Epstein, E. H. Jr., and de Sauvage, F. J. (1998). Activating smoothened mutations in sporadic basal-cell carcinoma. Nature 391, 90-92.
89. Yan, M., Callahan, C. A., Beyer, J. C., Allamneni, K. P., Zhang, G., Ridgway, J. B., Niessen, K., and Plowman, G. D. (2010). Chronic DLL4 blockade induces vascular neoplasms. Nature 463, E6-E7.
90. Yang, Z. J., Ellis, T., Markant, S. L., Read, T. A., Kessler, J. D., Bourboulas, M., Schüller, U., Machold, R., Fishell, G., Rowitch, D. H., Wainwright, B. J., and Wechsler-Reya, R. J. (2008). Medulloblastoma can be initiated by deletion of patched in lineage-restricted progenitors or stem cells. Cancer Cell 14, 135-145.
91. Yauch, R. L., Gould, S. E., Scales, S. J., Tang, T., Tian, H., Ahn, C. P., Marshall, D., Fu, L., Januario, T., Kallop, D., Nannini-Pepe, M., Kotkow, K., Marsters, J. C., Rubin, L. L., and de Sauvage, F. J. (2008). A paracrine requirement for hedgehog signaling in cancer. Nature 455, 406-410.
92. Ying, M., Wang, S., Sang, Y., Sun, P., Lal, B., Goodwin, C. R., Guerrero-Cazares, H., Quinones-Hinojosa, A., Laterra, J., and Xia, S. (2011). Regulation of glioblastoma stem cells by retinoic acid: role for Notch pathway inhibition. Oncogene. doi: 10.1038/onc.2011.58 [Epub ahead of print].
93. Zhang, B., Strauss, A. C., Chu, S., Li, M., Ho, Y., Shiang, K. D., Snyder, D. S., Huettner, C. S., Shultz, L., Holyoake, T., and Bhatia, R. (2010). Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate. Cancer Cell 17, 427-442.
94. Zhao, C., Chen, A., Jamieson, C. H., Fereshteh, M., Abrahamsson, A., Blum, J., Kwon, H. Y., Kim, J., Chute, J. P., Rizzieri, D., Munchhof, M., VanArsdale, T., Beachy, P. A., and Reya, T. (2009). Hedgehog signaling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature 458, 776-779.
95. Zhou, B. B., and Elledge, S. J. (2000). The DNA damage response: putting checkpoints in perspective. Nature 408, 433-439.